Argyle Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Argyle Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.9M	Sell	18,364 -427	-2%	-$67.4K	1.79%	8
2026 Q2	$2.97M	Sell	18,791 -273	-1%	-$36.9K	1.87%	7
2026 Q1	$2.44M	Sell	19,064 -1,648	-8%	-$206K	1.75%	11
2025 Q4	$2.53M	Sell	20,712 -3,327	-14%	-$381K	1.84%	10
2025 Q3	$2.41M	Sell	24,039 -1,845	-7%	-$166K	1.73%	10
2025 Q2	$2.15M	Sell	25,884 -1,081	-4%	-$86.2K	1.77%	9
2025 Q1	$2.19M	Buy	26,965 +4,582	+20%	+$410K	1.87%	9
2024 Q4	$2.02M	Buy	+22,383	New	+$2.17M	1.73%	9

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Investure LLC Charlottesville, Virginia $1.83B AUM 14.32% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Argyle Capital Partners's XBI Position: Q3 2026 in Review

Argyle Capital Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2.3% in Q3 2026, selling an estimated $67.4K and leaving 18,364 shares worth $2.9M. The position accounts for 1.79% of the portfolio, ranked #8.

Argyle Capital Partners first reported a position in XBI in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.97M in Q2 2026. 559 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Argyle Capital Partners held 18,364 shares of State Street SPDR S&P Biotech ETF worth $2.9M as of Q3 2026.
Argyle Capital Partners sold 427 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $67.4K.
State Street SPDR S&P Biotech ETF made up 1.79% of Argyle Capital Partners's portfolio in Q3 2026, its #8 holding.
Argyle Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 8 quarters since.
Argyle Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $2.97M in Q2 2026.
559 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Argyle Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.